Hello, Fool! | Login | Signup | My Fool
Jan 9, 2009 8:41 PM ET | Feedback | Site Changes | Help
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
View All Commentary (ENMD)
Recs
amteague777 (97.80) Submitted: 6/01/07 6:27 PM : Start Price: $1.90 ENMD Score: 45.92
Underperformed s&p since 1996 except for blip in 2000. Negative net income 2004-2007. Currently negative cash flow, ROE, ROA.
Report this Post Replies: 1 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
wofat50 (< 20) Submitted: 7/31/08 5:28 PM
Recs: 0 | Rec This
what do you expect, it's a biotech co with phase II drug candidates! Of course they're cash flow negative! You're betting on the pipeline!
Report this Post Reply
Terms & Conditions
RSS Headlines
Fool UK